NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $46 | $14 | $103 | $0 |
| % Growth | 223.4% | -86.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $46 | $14 | $103 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $151 | $159 | $87 | $29 |
| G&A Expenses | $70 | $38 | $20 | $5 |
| SG&A Expenses | $70 | $38 | $20 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $222 | $197 | $106 | $35 |
| Operating Income | -$176 | -$183 | -$4 | -$35 |
| % Margin | -386.9% | -1,298.6% | -3.5% | – |
| Other Income/Exp. Net | -$65 | $6 | -$19 | -$7 |
| Pre-Tax Income | -$242 | -$177 | -$23 | -$42 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$242 | -$177 | -$23 | -$42 |
| % Margin | -530.3% | -1,255.8% | -22% | – |
| EPS | -2.56 | -2.15 | -1.11 | -3.34 |
| % Growth | -19.1% | -93.7% | 66.8% | – |
| EPS Diluted | -2.56 | -2.15 | -1.11 | -3.34 |
| Weighted Avg Shares Out | 94 | 82 | 19 | 18 |
| Weighted Avg Shares Out Dil | 94 | 82 | 19 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $10 | $0 | $0 |
| Interest Expense | $0 | $7 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$241 | -$177 | -$22 | -$41 |
| % Margin | -530% | -1,255.2% | -21.8% | – |